摘要
目的 :观察黄杨宁与倍他乐克联用对频发室性早搏病人心率变异性(HRV )的影响。方法 :68例经 2 4h动态心电图证实的频发室性早搏病人随机分为观察组及对照组 ,每组各 3 4例 ,观察组以黄杨宁 ( 2mg ,每日 3次 )及倍他乐克 ( 2 5mg ,每日 2次 )口服 ,对照组以同等剂量的倍他乐克口服 ,疗程为 4周 ,治疗前后以动态心电图时域分析法对其心率变异性指标进行检测 ,并与对照组进行比较。结果 :与治疗前相比 ,两组治疗后代表心率总变异程度的指标SDNN、SDANNI、SDNNI及代表迷走神经功能的指标rMSSD、pNN50 均有显著升高 (P <0 .0 5或P <0 .0 1) ;治疗后各指标变化在观察组较对照组更明显 ,两组间比较具有统计学意义(P <0 .0 5或P <0 .0 1) ;观察组与对照组抗室性早搏总有效率分别为70 .6%和 5 2 .9% ,组间比较具有统计学意义 (P <0 .0 1) ;结论 :黄杨宁与倍他乐克联用不仅能有效治疗室性早搏 ,而且能提高心率变异性 ,改善其预后。
Objective:To investigate the change of the heart rate variability(HRV) after the treatment with Huangyangning combiled with Betaloc on premature ventricular complexes(PVC) patients. Methods:68 cases of PVC patients were randomizedly divided into two groups: group 1(n=34)were treated by Huangyangning(2 mg, three times a day) combiled with Betaloc(25 mg, twice a day); group 2(n=34)were treated by Betaloc(25 mg, twice a day); the index of HRV such as SDNN, SDANNI, SDNNI, rMSSD and pNN 50 were observed by 24 h ambulatory ECG before and after four weeks , treatment. Results:After treatment, the SDNN, SDANNI, SDNNI that represented the total HRV and the rMSSD, pNN 50 that showed the vagal fuction were all improved significantly in two groups(P<0.05 or P<0.01), those changes were more significant in group 1 than in group 2(P<0.05 or P<0.01), the total efficiency of reducing PVC in group 1 and group 2 were 70.6% and 52.9% respectively, the difference was also significant(P<0.01). Conclusion:Huangyangning combining with Betaloc can not only reduce the PVC and inprove the symptom, but also increase the HRV and improve the prognosis.
出处
《中西医结合心脑血管病杂志》
2003年第11期623-624,共2页
Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
